MBX Biosciences (MBX) Net Cash Flow (2023 - 2026)

MBX Biosciences has disclosed Net Cash Flow across 4 years of filings, most recently posting -$29.9 million for Q1 2026.

• Net Cash Flow for Q1 2026 came in at -$29.9 million, down 53.59% year-over-year; the trailing twelve-month figure through Mar 2026 was $15.5 million (up 380.99% YoY), and the FY2025 annual result was $25.9 million, up 37.76% from the prior year.
• Net Cash Flow came in at -$29.9 million for Q1 2026 at MBX Biosciences, up from -$147.8 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $183.3 million in Q3 2025 to a low of -$147.8 million in Q4 2025.
• The 4-year median for Net Cash Flow is -$21.2 million (2024), against an average of -$2.5 million.
• Peak annual rise in Net Cash Flow reached 143.09% in 2025, while the deepest fall reached 496.74% in 2025.
• MBX Biosciences' Net Cash Flow stood at -$40.1 million in 2023, then sank by 108.36% to -$83.5 million in 2024, then tumbled by 77.02% to -$147.8 million in 2025, then surged by 79.8% to -$29.9 million in 2026.
• The last three Net Cash Flow figures came in at -$29.9 million (Q1 2026), -$147.8 million (Q4 2025), and $183.3 million (Q3 2025), per Business Quant data.